Actinium Pharmaceuticals Inc (ATNM) Short Interest Update
Actinium Pharmaceuticals Inc (NYSE:ATNM) was the target of a large increase in short interest during the month of October. As of October 14th, there was short interest totalling 2,170,966 shares, an increase of 2.9% from the September 30th total of 2,109,473 shares. Currently, 4.3% of the shares of the company are short sold. Based on an average daily trading volume, of 786,479 shares, the days-to-cover ratio is currently 2.8 days.
Shares of Actinium Pharmaceuticals (NYSE:ATNM) traded down 2.83% on Tuesday, hitting $1.03. The company had a trading volume of 240,378 shares. Actinium Pharmaceuticals has a 52 week low of $1.02 and a 52 week high of $3.50. The company’s market capitalization is $49.15 million. The stock’s 50-day moving average is $1.47 and its 200 day moving average is $1.71.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).
Receive News & Ratings for Actinium Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts" ratings for Actinium Pharmaceuticals Inc and related companies with MarketBeat.com"s FREE daily email newsletter.